Viewing Study NCT03081234


Ignite Creation Date: 2025-12-25 @ 2:32 AM
Ignite Modification Date: 2025-12-30 @ 8:17 AM
Study NCT ID: NCT03081234
Status: WITHDRAWN
Last Update Posted: 2018-03-15
First Post: 2017-03-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module